Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

Blood

Volumn 114, Issue 18, 2009, Pages 3769-3772

  Pardanani, Animesh ^a   Lim, Ken Hong ^a,b   Lasho, Terra L ^a   Finke, Christy ^a   McClure, Rebecca F ^a   Li, Chin Yang ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CELL LINEAGE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE ASSOCIATION; EOSINOPHILIA; FEMALE; FIP1L1 PDGFRA GENE; GENE; HEMATOLOGIC MALIGNANCY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC MASTOCYTOSIS; BLOOD DISEASE; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; SECOND CANCER;

CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; AGED; AGED, 80 AND OVER; EOSINOPHILIA; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 70449706224     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-220145     Document Type: Article

References (10)

1. Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (4th ed). Lyon, France: International Agency for Research and Cancer; 2008:54-63.
2. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62(5):965-972.
3. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57(6):604-608.
4. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000;28(2):140-147.
5. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7): 2366-2372.
6. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100(2):661-665.
7. Kim Y, Weiss LM, Chen YY, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res. 2007;31(12): 1749-1754.
8. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23): 5727-5736.
9. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-453.
10. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109(11): 2279-2284.